Prediction of treatment outcomes in psychiatry-where do we stand?

Dialogues in Clinical Neuroscience

Volumn 16, Issue 4, 2014, Pages 455-464

  McMahon, Francis J ^a,b,c  

^a International Society of Psychiatric Genetics   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Adverse event; Biomarker; Personalized medicine; Pharmacogenetics

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CLINICAL FEATURE; COMORBIDITY; GENETIC MARKER; HUMAN; PATIENT COMPLIANCE; PREDICTION; PSYCHIATRIC DIAGNOSIS; PSYCHIATRY; SCIENCE; TREATMENT OUTCOME; MENTAL DISORDERS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROCEDURES; TRENDS;

HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PRECISION MEDICINE; PSYCHIATRY;

EID: 84925306502     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. McMahon FJ, Insel TR. Pharmacogenomics and personalized medicine in neuropsychiatry. Neuron. 2012;74:773-776.
2. Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract. 2010;16:306-324.
3. Auffray C, Hood L. Editorial: Systems biology and personalized medicine - the future is now. Biotechnol J. 2012;7:938-939.
4. Drozda K, Muller DJ, Bishop JR. Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy. 2014;34:166-84.
5. Hoehe MR, Kroslak T. Genetic variation and pharmacogenomics: concepts, facts, and challenges. Dialogues Clin Neurosci. 2004;6:5-25
6. Wacholder S. Population risk measures. Epidemiol. 2005;16:594.
7. Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron. 2010;68:201-206.
8. Gottesman O, Kuivaniemi H, Tromp G, et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med. 2013;15:761-771.
9. Siontis GCM, Tzoulaki I, Ioannidis JPA. Predicting death: an empirical evaluation of predictive tools for mortality. Arch Intern Med. 2011;171:1721-1726.
10. Freedman RA, Winer EP. Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer. Breast. 2010;19:69-75.
11. Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PMM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ. 2012;344:e686.
12. Receiver Operating Characteristic Curve. Available at: http://www. adscience.eu/uploads/ckfiles/files/html_files/StatEL/statel_ROC_curve.htm. Accessed October 2014.
13. Aldous SJ, Richards M, Cullen L, Troughton R, Than M. Diagnostic and prognostic utility of early measurement with high-sensitivity troponin T assay in patients presenting with chest pain. Can Med Assoc J. 2012;184:e260-e268.
14. Wacholder S. Clinical utility in evaluation of risk models. Am J Epidemiol. 2012;176:495-496.
15. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ. 1998;317:307-312.
16. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287:1840-1847.
17. Jane-wit D, Horwitz RI, Concato J. Variation in results from randomized, controlled trials: stochastic or systematic? J Clin Epidemiol. 2010;63:56- 63.
18. Wacholder S. Design issues in case-control studies. Stat Methods Med Res. 1995;4:293-309.
19. Wacholder S. Bias in full cohort and nested case-control studies? Epidemiol. 2009;20:339-340.
20. Tzoulaki I, Liberopoulos G, Ioannidis JPA. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009;302:2345-2352.
21. Kraft P. Curses--winner's and otherwise--in genetic epidemiology. Epidemiol. 2008;19:649-651.
22. Xiao R, Boehnke M. Quantifying and correcting for the winner's curse in genetic association studies. Genet Epidemiol. 2009;33:453-462.
23. Zollner S, Pritchard JK. Overcoming the winner's curse: estimating penetrance parameters from case-control data. Am J Hum Genet. 2007;80:605-615.
24. Ioannidis JPA. To replicate or not to replicate: the case of pharmacogenetic studies: have pharmacogenomics failed, or do they just need larger- scale evidence and more replication? Circ Cardiovasc Genet. 2013;6:413- 418.
25. Cohen RM, Greenberg JM, IsHak WW. Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression to measure treatment impact and recovery in MDD. JAMA Psychiatry. 2013;70:343-350.
26. Katz AJ, Dusetzina SB, Farley JF, et al. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. Pharmacotherapy. 2012;32:234-243.
27. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457-494.
28. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29:15-31.
29. Deckersbach T, Peters AT, Sylvia L, et al. Do comorbid anxiety disorders moderate the effects of psychotherapy for bipolar disorder? Results from STEP-BD. Am J Psychiatry. 2014;171:178-186.
30. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
31. Norton JC. The Trail Making Test and Bender Background Interference Procedure as screening devices. J Clin Psychol. 1978;34:916-922.
32. Eisner E, Drake R, Barrowclough C. Assessing early signs of relapse in psychosis: review and future directions. Clin Psychol Rev. 2013;33:637-653.
33. Ishak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). J Affect Disord. 2013;151:59-65.
34. Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63:942-947.
35. McGrath LM, Cornelis MC, Lee PH, et al. Genetic predictors of risk and resilience in psychiatric disorders: a cross-disorder genome-wide association study of functional impairment in major depressive disorder, bipolar disorder, and schizophrenia. Am J Med Genet Part B Neuropsychiatr Genet. 2013;162B:779-788.
36. Suzuki T, Uchida H, Watanabe K, Kashima H. Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol Bull. 2011;44:32-60.
37. Awad AG. Drug therapy in schizophrenia--variability of outcome and prediction of response. Can J Psychiatry. 1989;34:711-720.
38. Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord. 2005;7:404-417.
39. Petursson H. Prediction of lithium response. Compr Psychiatry. 1979;20:226-241.
40. Kemp AH, Gordon E, Rush AJ, Williams LM. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr. 2008;13:1066-1086.
41. Bennabi D, Vandel P, Papaxanthis C, Pozzo T, Haffen E. Psychomotor retardation in depression: a systematic review of diagnostic, pathophysiologic, and therapeutic implications. BioMed Res Int. 2013;2013:158746.
42. Perlis RH, Uher R, Ostacher M, et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry. 2011;68:351-360.
43. Sung SC, Wisniewski SR, Balasubramani GK, et al. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. Psychol Med. 2013;43:945-960.
44. Kozel FA, Trivedi MH, Wisniewski SR, et al. Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Am J Geriatr Psychiatry. 2008;16:58-64.
45. Perlis RH, Dennehy EB, Miklowitz DJ, et al. Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. Bipolar Disord. 2009;11:391-400.
46. Zisook S, Lesser I, Stewart JW, et al. Effect of age at onset on the course of major depressive disorder. Am J Psychiatry. 2007;164:1539-1546.
47. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303:47- 53.
48. Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010;12:345-357.
49. Cuthbert BN, Kozak MJ. Constructing constructs for psychopathology: the NIMH research domain criteria. J Abnorm Psychol. 2013;122:928- 937.
50. Hagan JJ, Jones DNC. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull. 2005;31:830-853.
51. Harvey PD, Bowie CR. Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches. Psychiatr Clin North Am. 2012;35:683-698.
52. Sarfati Y, Hardy-Bayle M-C. Could cognitive vulnerability identify high-risk subjects for schizophrenia? Am J Med Genet. 2002;114:893- 897.
53. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233-255.
54. Murphy EJ, Kassem L, Chemerinski A, Rush AJ, Laje G, McMahon FJ. Retention and attrition among African Americans in the STAR*D study: what causes research volunteers to stay or stray? Depress Anxiety. 2013;30:1137-1144.
55. Kerber KB, Wisniewski SR, Luther JF, et al. Effects of heart disease on depression treatment: results from the COMED study. Gen Hosp Psychiatry. 2012;34:24-34.
56. Hedayati SS, Minhajuddin AT, Afshar M, Toto RD, Trivedi MH, Rush AJ. Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. JAMA. 2010;303:1946-1953.
57. Bryan C, Songer T, Brooks MM, et al. The impact of diabetes on depression treatment outcomes. Gen Hosp Psychiatry. 2010;32:33-41.
58. Gollan JK, Fava M, Kurian B, et al. What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? Depress. Anxiety 2012;29:94-101.
59. Davis LL, Pilkinton P, Wisniewski SR, et al. Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. Depress Anxiety. 2012;29:111-122.
60. Davis LL, Wisniewski SR, Howland RH, et al. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend. 2010;107:161-170.
61. Li X, Yu K, Mei S, et al. HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: Evidence from a meta-analysis of nine case-control studies. Drug Res Stuttg. 2014; epub May 28 2014.
62. Gratten J, Wray NR, Keller MC, Visscher PM. Large-scale genomics unveils the genetic architecture of psychiatric disorders. Nat Neurosci. 2014;17:782-790.
63. Le-Niculescu H, Patel SD, Bhat M, et al. Convergent functional genomics of genome-wide association data for bipolar disorder: comprehensive identification of candidate genes, pathways and mechanisms. Am J Med Genet Part B Neuropsychiatr Genet. 2009;150B:155-181.
64. Li-Pook-Than J, Snyder M. iPOP goes the world: integrated personalized Omics profiling and the road toward improved health care. Chem Biol. 2013;20:660-666.
65. Hood L, Tian Q. Systems approaches to biology and disease enable translational systems medicine. Genomics Proteomics Bioinformatics. 2012;10:181-185.
66. Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22:1790-1797.
67. Janssens ACJW, Ioannidis JPA, van Duijn CM, Little J, Khoury MJ. Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. Genet Med. 2011;13:453-456.
68. Ioannidis JPA. Personalized genetic prediction: too limited, too expensive, or too soon? Ann Intern Med. 2009;150:139-141.
69. Greshake B, Bayer PE, Rausch H, Reda J. openSNP--a crowdsourced web resource for personal genomics. PLoS One. 2014;9:e89204.
70. Gao Y, Galante M, El-Mallakh J, et al. BDNF expression in lymphoblastoid cell lines carrying BDNF SNPs associated with bipolar disorder. Psychiatr Genet. 2012;22:253-255.
71. Evans KC, Dougherty DD, Pollack MH, Rauch SL. Using neuroimaging to predict treatment response in mood and anxiety disorders. Ann Clin Psychiatry. 2006;18:33-42.
72. Fu CHY, Costafreda SG. Neuroimaging-based biomarkers in psychiatry: clinical opportunities of a paradigm shift. Can J Psychiatry. 2013;58:499- 508.
73. MacQueen GM. Magnetic resonance imaging and prediction of outcome in patients with major depressive disorder. J Psychiatry Neurosci. 2009;34:343-349.
74. Kozel FA, Rao U, Lu H, et al. Functional connectivity of brain structures correlates with treatment outcome in major depressive disorder. Front Psychiatry. 2011;2:7.
75. Tomasik J, Rahmoune H, Guest PC, Bahn S. Neuroimmune biomarkers in schizophrenia. Schizophr Res. 2014; epub 12 August.
76. Jaworska N, Protzner A. Electrocortical features of depression and their clinical utility in assessing antidepressant treatment outcome. Can J Psychiatry Rev Can Psychiatr. 2013;58:509-514.
77. Cook IA, Hunter AM, Gilmer WS, et al. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) trial. J Clin Psychiatry. 2013;74:51-56.
78. Guest PC, Martins-de-Souza D, Schwarz E, et al. Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. Genome Med. 2013;5:25.
79. Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011;473:221-225.
80. Wen Z, Nguyen HN, Guo Z, et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature. 2014;515:414-418.
81. Trivedi MH. Modeling predictors, moderators and mediators of treatment outcome and resistance in depression. Biol Psychiatry. 2013;74:2-4.
82. Leuchter AF, Cook IA, Marangell LB, et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study. Psychiatry Res. 2009;169:124-131.
83. Murphy E, Hou L, Maher BS, et al. Race, genetic ancestry and response to antidepressant treatment for major depression. Neuropsychopharmacol. 2013;38:2598-2606.
84. Tomita T, Yasui-Furukori N, Sato Y, et al. Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response. Neuropsychiatr Dis Treat. 2014;10:599-606.
85. Kemp DE, Ganocy SJ, Brecher M, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011;130:171-179.
86. Lewis CC, Simons AD, Kim HK. The role of early symptom trajectories and pretreatment variables in predicting treatment response to cognitive behavioral therapy. J Consult Clin Psychol. 2012;80:525-534.
87. Dreimuller N, Schlicht KF, Wagner S, et al. Early reactions of brainderived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression. Neuropharmacology. 2012;62:264-269.
88. Correll CU, Zhao J, Carson W, et al. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes. J Am Acad Child Adolesc Psychiatry. 2013;52:689-698.
89. Stentebjerg-Olesen M, Jeppesen P, Pagsberg AK, et al. Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. J Child Adolesc Psychopharmacol. 2013;23:665-675.
90. Buitelaar JK, Van der Gaag RJ, Swaab-Barneveld H, Kuiper M. Prediction of clinical response to methylphenidate in children with attention- deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:1025-1032.
91. Pyeritz RE. The family history: the first genetic test, and still useful after all those years? Genet Med. 2012;14:3-9.
92. Berg AO, Baird MA, Botkin JR, et al. National Institutes of Health State-of-the-Science Conference Statement: Family History and Improving Health. Ann Intern Med. 2009;151:872-877.
93. Do CB, Hinds DA, Francke U, Eriksson N. Comparison of family history and SNPs for predicting risk of complex disease. PLoS Genet. 2012;8:e1002973.
94. Wilson BJ, Qureshi N, Santaguida P, et al. Systematic review: family history in risk assessment for common diseases. Ann Intern Med. 2009;151:878-885.
95. Ananth J, Pecknold JC. Prediction of lithium response in affective disorders. J Clin Psychiatry. 1978;39:95-100.
96. Wattendorf DJ, Hadley DW. Family history: the three-generation pedigree. Am Fam Physician. 2005;72:441-448.
97. Kendler KS. Family history information in biomedical research. J Contin Educ Health Prof. 2001;21:215-223.